Amneal adds blackberry flavoring to generic diabetes drug
BRIDGEWATER, N.J. — Amneal Pharmaceuticals is adding blackberry flavoring to a generic diabetes drug following feedback from customers, the company said Wednesday.
Amneal announced the changes to its metformin hydrochloride immediate-release tablets in the 500-mg, 850-mg and 1,000-mg strengths, designed to cover up the smell of metformin.
The company said the blackberry-flavored metformin, manufactured at its Brookhaven, N.Y., factory, will begin shipping this month with new national drug code numbers. The drug is a generic version of Glucophage, made by Merck Sante S.A.S., a subsidiary of Germany-based Merck KGaA, a separate and distinct company from U.S.-based Merck that operates under the name EMD Serono in the United States.
No comments found
More than one-third of dispensed prescriptions sent electronically in 2011, report finds
ARLINGTON, Va. — The number of prescriptions being sent electronically jumped by 75% between 2010 and 2011, while almost all of the retail pharmacies in the country are connected for e-prescribing, according to a new report by the country’s largest e-prescribing network.
According to a report scheduled for release Thursday, Surescripts found that the number of pharmacies connected to the Surescripts network has become almost total. Nearly 57,000 retail pharmacies — out of the 62,461 chain and independent pharmacies in the country overall — are connected to Surescripts’ network, compared with 46,000 in 2008. The current figure represents more than 98% of chain pharmacies and 79% of independents.
In all, 570 million prescriptions, or 36% of the total, were routed electronically by prescribers to pharmacies by the end of 2011, compared with 326 million, or 22% of the total, in 2010. Meanwhile, 58% of office-based physicians were e-prescribing in 2011, compared with 1-in-10 in 2008.
The report also showed an improvement in medication adherence due to e-prescribing, with 76.5% of electronically routed prescriptions being picked up, compared with 69.5% of those sent through traditional means, with a "consistent" increase in first-fill adherence of 10%, creating potential savings of between $140 million to $240 million over 10 years.
"This remarkable growth in adoption and use has transformed one of the most common transactions in health care into a mainstream electronic healthcare tool," Surescripts president and CEO Harry Totonis wrote in the report. "Electronic routing of prescriptions on the Surescripts network accounted for more than 1-in-3 prescriptions that were picked up by patients at community pharmacies. As states implement e-prescribing for controlled substances … these new types of transactions will drive additional use of e-prescribing."
One major contributor to growth is government incentives for electronic health records and e-prescribing under the Health Information Technology for Economic and Clinical Health, or HITECH, Act, which is providing up to $30 billion in incentives for prescribers who adopt electronic health records and meet the government’s "meaningful use" requirements. According to the report, of a cohort of physicians who adopted and began using e-prescribing in 2008, as many as 60% of them have met the initial stage of meaningful use, while 38% would meet the proposed second stage; e-prescribing is one of the core objectives of stage 1 meaningful use, which requires a provider to route more than 40% of prescriptions electronically. So far, the Centers for Medicare and Medicaid Services has doled out almost $4 billion in payments to providers and hospitals.
CORRECTION: An earlier version of this story stated that the incentives for adoption of electronic health records are given out by the Centers for Disease Control and Prevention. The incentives are granted by the Centers for Medicare and Medicaid Services. The story has been corrected.
Ahier: Thank you for pointing out the error in the story, which we have now corrected. Alaric DeArment Associate Editor, Drug Store News
The incentives are not paid by CDC! The $4 billion comes via CMS, a separate agency...
CMS warns against protocol violations of Medicare Part D prescription transfers
BALTIMORE — The Centers for Medicare and Medicaid Services earlier this month released a memo to all Part D sponsors, warning them that the agency has "observed an increase in beneficiary complaints related to the transfer of prescriptions from retail pharmacies to either mail-order or specialty pharmacy without their explicit consent."
According to the memo, the transferring of a prescription from one pharmacy to another that is not initiated by the patient is prohibited without the patient’s consent. Unsolicited phone calls made by the plan or pharmacy seeking permission from beneficiaries to transfer a prescription are not permitted.
Also not permitted is the use of prior authorization forms. "The use of other mechanisms, such as prior authorization forms, to steer a beneficiary into a mail-order pharmacy is against CMS requirements and should be discontinued immediately," wrote Cynthia Tudor, director CMS’ Medicare Drug Benefit and C & D Data Group. "The choice of which network pharmacy to use is at the sole discretion and convenience of the beneficiary."
"This action by CMS is a step in the right direction," noted Kevin Schweers, SVP public affairs for the National Community Pharmacists Association, in a blog posted Wednesday. "Hopefully, the agency continues to take this issue seriously and applies greater oversight in the future."
In December, NCPA communicated to CMS possible abuses of the protocol Part D plans must follow to document a patient’s affirmative decision to switch from one pharmacy to another. In a letter to CMS, NCPA noted: "We have learned that a number of Part D plans across the country are calling and harassing beneficiaries to transfer their prescriptions to a preferred network pharmacy (most commonly a mail-order pharmacy). These plans repeatedly call beneficiaries to make the change. Some plans are even moving patients to mail order without telling them, such that the patient fills a prescription at their community pharmacy and receives a duplicate prescription in the mail.”
For Schweers’ full blog post, click here.
No comments found